Modulators and methods of use

File for Quick & Easy Patent Protection with PowerPatent.

The Stemcentrx, Inc. patent solves the following problem:

Stem and progenitor cell inequality and cell proliferation in the normal process to continue to act in concert to support tissue growth during organogenesis, and cell replacement and repair of the tissues during the entire life of all living organisms. Difference and proliferation decision always controlled in many things and signals that maintain balance in cell fate decisions and tissue architecture. Normal tissue architecture to remain as a result of cells responding to microenvironmental cues that control cell division and tissue maturation. Therefore, cell proliferation and diversity often it is only necessary for the replacement of damaged or dead cells or for growth. Sadly, disruption of cell proliferation and / or divisions resulting from the ten thousand things including, for example, understanding or overabundance of different chemical signals, before changing microenvironments, genetic mutation or some combination thereof. When the normal cellular proliferation and / or division or disturbed somewhat disrupted it can lead to various diseases or disorders including cancer.

Our analysis of this patent is as follows:

Stemcentrx, Inc.’s patent US 9458231 B2 deals with Modulators and methods of use.
The new modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-C5a binding moieties with high blocking activity

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Inflarx Gmbh patent solves the following problem:

C5a is cleaved from C5 on complement activation. Among the complement activation products, C5a is one of the most potent inflammatory peptide, with a broad spectrum of functions (Guo and Ward, 2005). C5a is a glycoprotein present in the blood of healthy people with a molecular weight of 11.2 kDa. The polypeptide of C5a contains 74 amino acids, accounting for a molecular weight of 8.2 kDa while the carbohydrate portion causes approximately 3 kDa. C5a exerts its effect through the high-affinity C5a receptor (C5aR and C5L2) (Ward 2009). C5aR belongs to the rhodopsin family of G-protein-coupled receptor with seven transmembrane portion; C5L2 similar but not G-protein-coupled. It is now believed that C5a exerts its biological functions primarily through C5a-C5aR interaction, as in certain biological responses found in C5a-C5L2 interaction. C5aR is widely expressed in myeloid cells including neutrophils, eosinophils, basophils, and monocytes, and nonmyeloid cells in many organs, particularly the lungs and liver, indicating the importance of C5a / C5aR signaling. C5a has a variety of biological functions (Guo and Ward, 2005). C5a is a strong chemoattractant for neutrophil chemotactic activity for monocytes and macrophages. C5a causes an oxidative burst (O2 consumption) in neutrophils and enhances phagocytosis and release granular enzymes. C5a also found a vasodilator. C5a is shown to be involved in the modulation of cytokine expression from different types of cell, to improve the expression of adhesion molecules on neutrophils. It found that C5a can be very harmful when it is more than a disease settings, as it is a strong inducer and enhancer for the inflammatory response-moving stream of inflammatory chain reaction. High doses of C5a lead to nonspecific chemotactic desensitization of neutrophils, thereby causing broad act (Huber-Lang et al. 2001a).

Our analysis of this patent is as follows:

Inflarx Gmbh’s patent US 9458233 B2 deals with Anti-C5a binding moieties with high blocking activity.
The present invention relates to binding moieties that specifically binds to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties of anti-C5a antibodies that bind this conformational epitope. The binding moieties described here are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as systemic inflammatory response syndrome (SIRS), and different levels of sepsis and sepsis, severe sepsis, and septic shock.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Direct drive instruments and methods of use

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Boston Scientific Scimed, Inc. patent solves the following problem:

Minimally invasive surgical instruments, endoscopic and laparoscopic devices, provides surgical access to surgical areas while minimizing patient trauma. Although the growing capabilities of therapeutic devices allow physicians to perform a growing variety of operations with the traditional minimally invasive routes, further changes can surgical access through even less invasive routes . At present some robotic systems have been proposed to allow surgical access through a natural orifice. The user interface is isolated from the surgical instrument and / or end effectors. Unfortunately, these systems are often costly and complex. Moreover, they failed to give the user tactile feedback traditional devices can.

Our analysis of this patent is as follows:

Boston Scientific Scimed, Inc.’s patent US 9456877 B2 deals with Direct drive instruments and methods of use.
Said there are various instruments, systems, and methods of use. The instruments may have various members of the control and / or control rod in various degrees of freedom. Furthermore, the controlling member may include various control mechanisms to transfer user inputs from one rod to a distal portion of the instrument. On the one hand, an instrument may comprise a control member and a catheter. catheter be adjustably and / or detachably connected to the control member.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Enhanced photo-catalytic cells

File for Quick & Easy Patent Protection with PowerPatent.

The Puradigm, Llc patent solves the following problem:

The present invention generally relates to methods and apparatus for the production of an upgraded ionized cloud bactericidal molecules.

Our analysis of this patent is as follows:

Puradigm, Llc’s patent US 9457122 B2 deals with Enhanced photo-catalytic cells.
According to an image of the present invention, an apparatus for ionizing air includes a first reflector and a first target. The first reflector receives direct UV energy (from a UV emitter) and it shows in the form of UV energy. The first target containing face also receive direct UV energy (from the UV emitter). The first target of an outer surface to receive the UV energy from the first reflector. The first target face coated with a photo-catalytic coating. The first target will be the passage between the faces.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Molecular Partners Ag patent solves the following problem:

The following discussion of the background is only provided to assist readers in understanding the invention and is not admitted to describe or constitute prior art to the present invention.

Our analysis of this patent is as follows:

Molecular Partners Ag’s patent US 9458211 B1 deals with Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains.
Bag-ong designed ankyrin repeat domains with binding specificity for serum albumin, artificial binding protein that contains at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as artificial binding protein that contains the at least a designed ankyrin repeat domains with binding specificity for hepatocyte growth factor (HGF), at least a designed ankyrin repeat domains with binding specificity for vascular endothelial growth that (VEGF-A), and at least two designed ankyrin repeat domains with binding specificity for serum albumin described, as well as nucleic acid encoding the designed ankyrin repeat domains and artificial binding proteins, pharmaceutical compositions containing the designed ankyrin repeat domains, artificial binding protein or nucleic acid and to use those designed ankyrin repeat domains, artificial binding protein, nucleic acid composition or medicine to treat the disease.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Network policy and network device control

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Verizon Patent And Licensing Inc. patent solves the following problem:

The one network, to implement policies to govern how network traffic should be treated during the transmission. For example, a network device or policy enforcer device to implement policies, such as traffic queuing algorithms, bandwidth filtering, Quality of Service (QoS) policies, etc.

Our analysis of this patent is as follows:

Verizon Patent And Licensing Inc.’s patent US 9455923 B2 deals with Network policy and network device control.
A policy enforcer device may determine a price many controls include a control device. Many control may be associated with zones of a facility. The policy enforcer device to determine, based on the principle of plurality of controls, relative amount of bandwidth to allocate a total amount of available bandwidth, to place the facility; and to prevent one or more network devices to provide the determined amount of bandwidth to the zones facility.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

System for determining vibration characteristics of a motor vehicle

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Autoliv Development Ab patent solves the following problem:

Road conditions in the face, like a road surface consisting of lose gravel or smooth cobblestones, affect the car in a different way compared to the surface, the flat road that consists of smooth asphalt or cement.

Our analysis of this patent is as follows:

Autoliv Development Ab’s patent US 9453759 B2 deals with System for determining vibration characteristics of a motor vehicle.
A system for determining vibration characteristics of a motor vehicle with a sensing arrangement (8) adapted to sense vibrations in the car or on a car part, and an electronic processing means (11) adapted , adapted to the use of an algorithm (12) for evaluating the signal from the sensing arrangement (8) and to determine the nature of shocks based on evaluation. The algorithm (12) includes at least a support vector machine SVM (13 in a 13 g) adapted to output a probability that the current shaky nature of a particular pre-set kind of shaking behavior.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Inspection reporting including a 3D vehicle model

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Mobile Productivity, Llc patent solves the following problem:

Disclosure This generally relates to systems and methods for reporting and / or providing information associated with a vehicle inspection and, especially, to provide information on vehicle inspection, including a 3- dimensional (3D) model cars.

Our analysis of this patent is as follows:

Mobile Productivity, Llc’s patent US 9454854 B2 deals with Inspection reporting including a 3D vehicle model.
In a picture, create a visual reporting system in a 3-dimensional (3D) interactive vehicle inspection report covering 3D data model and inspection data for a particular vehicle. The inspection data, as recommended things well, associated with the graphical section 3D model vehicles. Furthermore, additional inspection data, such as instructional video or inspection, shall be given to a user seeking further details. By providing an interactive visual representation of data inspection, 3D inspection report provides a report that can be customized to provide different levels of detail for different users. Moreover, the 3D models provide a visually compact summary of the data inspection by marking the 3D model of things to repair for cars. Using the 3D inspection reports raise the possibility that the owner of the car saw the need for repair, resulting in more orders to repair the facility to repair.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Identifying affinity-matured human antibodies

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Xbiotech, Inc. patent solves the following problem:

Throughout the 19th and 20th century, scientists and doctors had been able to design custom therapeutic agents that are very specific for a biological target. By selectively attack the disease while saving healthy tissue, these magic bullets seemed to be ideal therapeutic agents. It was not until the early 1970s, however, this dream began to be realized when Kohler and Milstein (Nature 256: 495, 1975) a ground-breaking approach to making antigen (Ag) -specific monoclonal antibody (mAbs). This is perhaps one of the greatest events in the history of modern immunology. Using this new approach, much research, diagnostic, and therapeutic products developed in a combined market of hundreds of billions of dollars.

Our analysis of this patent is as follows:

Xbiotech, Inc.’s patent US 9453217 B2 deals with Identifying affinity-matured human antibodies.
Antigen-specific immunoglobulin V-regions identified from a library of nucleic acid amplified using polymerase chain reaction using the leader sequence-specific forward primers. The leader of the primers allow all V region sequences that develop (including with extensive mutation 5) without losing the original 5 V gene segment sequences. These libraries can be screened for antigen-specific V-region with the eukaryotic cells engineered to express the Amplified V region-encoding nucleic acid or bacteria using phage display techniques. In the latter, a second library V-region made use of a larger than conventional set at 5 V-region primers. The ranks of the errors introduced into the products nurtured in this way the correct use of information obtained in the products amplified V-region primers to screen the library created using the leader file primers. Amino acid is information from the part of the donor immunoglobulin can be used to help identify the nucleic acid encoding the heavy and light chains of the donor antibody as well as to design primers to amplify the nucleic acid .

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Selecting destinations or points of interest

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Google Inc. patent solves the following problem:

specification This relates in general to computerized travel services.

Our analysis of this patent is as follows:

Google Inc.’s patent US 9454544 B1 deals with Selecting destinations or points of interest.
Methods, systems, and apparatus, including computer programs encoded on computer storage media, for computerized travel services. One of the ways to include them to the point of interest or destinations associated with a place on the trip by querying a geographic data included on the data mapping to travel to the point of interest or destination; determine for each point of interest or destination: a number of travel related documents referring to the point of interest or destination, a number of travel related questions aimed at to the point of interest or destination, a number of geographically related to the point of interest or destination, and a popularity score based at least in part on the number of travel documents, the number to travel questions, and the number of photos; and selecting a chosen point of interest or destination based at least in part on the individual score popularity.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.